Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.

Oncotarget - 21 Jun 2016

Bianconi Maristella, Faloppi Luca, Loretelli Cristian, Zizzi Antonio, Giampieri Riccardo, Bittoni Alessandro, Andrikou Kalliopi, Del Prete Michela, Burattini Luciano, Montironi Rodolfo, Scartozzi Mario, Cascinu Stefano

Abstract excerpt

INTRODUCTION: Recent data from the COMPARZ study seem to suggest a non-inferiority of pazopanib confronted with sunitinib in PFS and OS. We previously reported how VEGF and VEGFR polymorphisms might have a predictive role in patients treated with first-line sunitinib. Aim of our study was to investigate whether tumour angiogenesis genotyping could influence clinical outcome in RCC patients treated with either...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indazoles

Share to Neovascularization, Pathologic

Share to Pyrroles

Share to Receptors, Vascular Endothelial Growth Factor

Share to Sulfonamides

Share to Sunitinib

Source

Open in PubMed Open full text

Identifiers

PMID: 27175586
DOI: 10.18632/oncotarget.9229
PMCID: PMC5122335

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.PMID 27175586Read ↗

Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.Semantic proximity Read ↗

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.Semantic proximity Read ↗

VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.Semantic proximity Read ↗

An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure.Semantic proximity Read ↗

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.Semantic proximity Read ↗

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.Semantic proximity Read ↗

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.Semantic proximity Read ↗

Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study.Semantic proximity Read ↗

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.Semantic proximity Read ↗

Variants in angiogenesis-related genes and the risk of clear cell renal cell carcinoma.Semantic proximity Read ↗

Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma.Semantic proximity Read ↗

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.